Quanterix Corp (QTRX) — Titan Protect Analysis

QTRX

Quanterix Corp

Healthcare · ·

$3.30

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$162M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-2.53

Based on estimated future earnings — lower means cheaper

Rev Growth

+20.1%

Year-over-year revenue change

Profit Margin

-71.9%

How much profit the company keeps from each dollar of revenue

ROE

-34.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$4.00

+21% from current price — median analyst estimate

Recommendation

HOLD

Consensus view from 3 analysts covering this stock

About Quanterix Corp

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all comp

https://www.quanterix.com

Country: United States Employees: 450 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.500

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0555

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.586

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-50.5%

Historical annualised return based on price data

Max Drawdown

-86.2%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.15

Moves slightly more than the broader market

52W High

$8.77

62% below the year high

52W Low

$2.40

38% above the year low

Avg Volume

1,125,155

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.35

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

12.52

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

45.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-59.1%

Profit from core operations before interest and tax

Free Cash Flow

$-21,983,500

Negative — the business is spending more than it generates

Revenue (TTM)

$145M

Total revenue over the last 12 months

Net Income

$-104,187,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$5.00

Target Median

$4.00

Target Low

$4.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go